Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jun 23, 2015 | Director | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 15,000 | -- | -- | |
| Jun 23, 2015 | Director | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 15,000 | -- | -- | |
| Jun 15, 2015 | SVP, Program Management | Open market or private sale of non-derivative or derivative security | Form 4 | 7,377 | $14.17 | -- | |
| Jun 15, 2015 | VP Clinical Ops & Data Mgmt | Open market or private sale of non-derivative or derivative security | Form 4 | 8,195 | $14.17 | -- | |
| Jun 08, 2015 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 55,000 | -- | -- | |
| Jun 08, 2015 | Director | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Form 4 | 8,936 | $12.65 | -- | |
| Apr 15, 2015 | Director | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 10,000 | -- | -- | |
| Apr 15, 2015 | Director | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 10,000 | -- | -- | |
| Apr 10, 2015 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 11,678 | -- | -- | |
| Mar 20, 2015 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 268,322 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.